Actinium Pharmaceuticals: Two Potential Blockbuster Therapies

• published: 16 Dec 2014
• views: 57

Dave Gentry, host of "The RedChip Money Report: Small Stocks Big Money," interviews Kaushik Dave, CEO of Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM). "The RedChip Money Report"™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The weekly program airs on Fox Business as well as Bloomberg UK, Bloomberg Europe, and Bloomberg Asia. For more information, visit: http://www.redchip.com/tv ATNM has two potential blockbuster therapies that have had excellent clinical trial results, with efficacy shown to be superior to the currently available treatment options none of which are FDA approved. These therapies have a lower overall cost of treatment, providing economic benefits to hospitals and ensuring that the Company can generate strong gross profits from its drugs. ATNM’s platform is highly scalable with multiple therapies in preclinical development and potential to improve upon existing biotech drugs. The median market cap of oncology companies with a lead therapy in phase 3 trials is $444 million. ATNM’s market cap as of this recording was under $200 million, which provides considerable upside, especially when considering the excellent clinical trial results from its two therapies and the long-term scalability of its Alpha Particle Immunotherapy platform technology (APIT). "The RedChip Money Report: Small Stocks Big Money"™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The weekly program airs on Fox Business as well as Bloomberg Europe and Bloomberg Asia. For more information, visit: http://www.redchip.com/tv